Potential of afatinib in the treatment of patients with HER2-positive breast cancer
Elena Geuna,1 Filippo Montemurro,2–4 Massimo Aglietta,1–3,5 Giorgio Valabrega1–3,51Division of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo, Turin, 2Institute for Cancer Research, Candiolo, Turin, 3Foundation of Piedmont Oncology,...
Guardado en:
Autores principales: | Geuna E, Montemurro F, Aglietta M, Valabrega G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5195c2dbcebd4e67a5602716f5648cfa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Recent advances in the development of breast cancer vaccines
por: Milani A, et al.
Publicado: (2014) -
Role of pertuzumab in the treatment of HER2-positive breast cancer
por: Hubalek M, et al.
Publicado: (2012) -
New developments in the treatment of HER2-positive breast cancer
por: Nahta R
Publicado: (2012) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015) -
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014)